Skip to content

"Genetic Material Often Deemed Non-Functional, 'Junk DNA', Holds Promise against Cancer: Its Beneficial Aspect Boasts Anti-Cancer Properties"

Scientists investigating novel methods to exploit ambiguous DNA segments, potentially stimulating the immune response to eradicate cancerous cells.

Genetic Material Previously Dismissed as "Junk" Shows Promise in Cancer Prevention: Positive...
Genetic Material Previously Dismissed as "Junk" Shows Promise in Cancer Prevention: Positive Aspects Revealed

"Genetic Material Often Deemed Non-Functional, 'Junk DNA', Holds Promise against Cancer: Its Beneficial Aspect Boasts Anti-Cancer Properties"

In a pioneering discovery, researchers from the University of Rochester have revealed the potential anti-cancer mechanisms of retrotransposons, often dubbed 'junk DNA,' in human cells. The study, spearheaded by Vera Gorbunova, Ph.D., the Doris Johns Cherry Professor of Biology and Medicine, and Andrei Seluanov, Ph.D., a professor of Biology and Medicine, was published in the latest issue of Nature Immunology.

The research, conducted at the Wilmot Cancer Institute, explores the potential use of retrotransposons in cancer treatment. If harnessed correctly, these DNA elements could stimulate the immune system to annihilate cancer cells, presenting a promising avenue for future therapies.

Gorbunova and Seluanov, who are also leaders in the University of Rochester Aging Institute, have long studied disease resistance and aging. Their work often involves the blind mole rat, an intriguing creature that lives underground and seems immune to cancer.

The researchers aim to use this newfound knowledge to find novel ways to halt cancer cell growth. However, it's crucial to note that when left unchecked, retrotransposons can spawn tumors.

Andrew McMahon and Brian Salzberg, who lead the Center for Stem Cell Biology and Regenerative Medicine at the University of Rochester, are also part of this collaborative endeavor.

The discovery could potentially pave the way for the development of new cancer treatments in the future. As the research progresses, the balance between the harmful and beneficial effects of retrotransposons in cancer will become increasingly apparent.

The report suggests that, contrary to popular belief, 'junk DNA' might not be so useless after all. In fact, it could prove to be a valuable scholar in the fight against cancer.

This exciting development in cancer research is another testament to the University of Rochester's commitment to advancing scientific understanding and improving human health.

Read also:

Latest